Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Al Mahtab, Mamun ^a   Bazinet, Michel ^b   Vaillant Vaillant, Andrew ^b  

^a BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY   (Bangladesh)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; HEAVY METAL; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; REP 2055; REP 2139CA; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VIRUS DNA; ALPHA INTERFERON; NUCLEIC ACID; POLYMER; THYMOSIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BANGLADESHI; CHILL; CHRONIC HEPATITIS B; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHAGIA; ENVIRONMENTAL EXPOSURE; FEVER; FOLLOW UP; GINGIVA BLEEDING; HEADACHE; HEAVY METAL POISONING; HEPATITIS B; HUMAN; HYPEREMIA; HYPOCALCEMIA; IMMUNOTHERAPY; INFUSION RELATED REACTION; INTERNATIONAL NORMALIZED RATIO; MONOTHERAPY; NONHUMAN; PETECHIA; PROTEIN BLOOD LEVEL; PRURITUS; SHIVERING; SIDE EFFECT; THROMBOCYTOPENIA; VIREMIA; VIRUS LOAD; ADOLESCENT; ADULT; ANALOGS AND DERIVATIVES; BANGLADESH; BLOOD; CLINICAL TRIAL; CYTOLOGY; DRUG EFFECTS; FEMALE; HEPATITIS B, CHRONIC; IMMUNOLOGY; LIVER CELL; MALE; MIDDLE AGED; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; BANGLADESH; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MALE; MIDDLE AGED; NUCLEIC ACIDS; PATIENT SAFETY; POLYMERS; THYMOSIN; YOUNG ADULT;

EID: 84974783000     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0156667     Document Type: Article

References (39)

1. Scheitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. The Lancet. 2015; 306: 1546-1555.
2. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. 2004; 350:1118-1129. PMID: 15014185
3. Moucari R, Lada O, Marcellin P. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009; 49: 1151-1157. doi: 10.1002/hep.22744 PMID: 19115222
4. Frenette CT, Gish RG. 2009. To "Be" or not to "Be": That is the question. Am. J. Gastroenterol. 2009; 104: 1948-1952. doi: 10.1038/ajg.2009.204 PMID: 19661938
5. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351: 1206-1217. PMID: 15371578
6. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354: 1001-1010. PMID: 16525137
7. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006; 354: 1011-1020. PMID: 16525138
8. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359: 2442-2455. doi: 10.1056/NEJMoa0802878 PMID: 19052126
9. Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol. 2011; 106: 1766-1773. doi: 10.1038/ajg.2011.253 PMID: 21826112
10. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analog therapy for chronic hepatitis B and prediction of HBsAg loss. J Inf Dis. 2011; 204: 415-418.
11. Noordeen F, Vaillant A. and Jilbert AR. Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. Antimicrob. Agents Chemother. 2013; 57: 5291-5298. doi: 10.1128/AAC.01003-13 PMID: 23939902
12. Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 2013; 57: 5299-5306. doi: 10.1128/AAC.01005-13 PMID: 23939904
13. Noordeen F, Scougall CA, Grosse A, Qiao Q, Ajilian BB, Reaiche-Miller et al. Therapeutic antiviral effect of the nucleic acid polymer REP 2055 against persistent duck hepatitis B virus infection. PLoS ONE. 2015; 10: e0140909. doi: 10.1371/journal.pone.0140909 PMID: 26560490
14. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006; 114: 1729-1735. PMID: 17030687
15. Cardin RD, Bravo FJ, Sewell AP, Cummins J, Flamand L, Juteau JM et al. Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection. Virol. J. 2007; 6:214.
16. Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK. A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasesne, G3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2004; 10: 5048-5057. PMID: 15297406
17. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. A phase I pharmacokinetic and pharmacodynamics study of OGX-011, a 2′methoxyethyl antisense oligonucleotide to clustrin, in patients with localized prostate cancer. J Nat Cancer Inst. 2005; 97: 1287-1296. PMID: 16145049
18. Lok ASF and McMahon B.J. Chronic hepatitis B. Hepatol. 2007; 45: 507-539.
19. Mata JE, Bishop MR, Tarantolo SR, Angel CR, Swanson SA, Iversen PL. Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment. Clin Toxicol.2000; 38: 383-387.
20. Rakib MA, Ali M, Akter MS, Bhuiyan MAH. Assessment of Heavy Metal (Pb, Zn, Cr and Cu) Content in Roadside Dust of Dhaka Metropolitan City, Bangladesh. Int. Res. J Environ. Sci. 2014; 3: 1-5.
21. Islam MS, Hoque MF. Concentration of heavy metals in vegetables around the industrial area of Dkaka city, Bangladesh and health risk assessment. Int, Food Res. J. 2014; 21: 2121-2126.
22. Tong S, von Schimding YE, Prapamontol T. Environmental lead exposure: a public health problem of global dimensions. Bulletin of the WHO. 2000; 78: 1068-1077.
23. Judge AD, Bola G, Lee ACH, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 2006; 13: 494-504. PMID: 16343994
24. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I. 2′-O-methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 2007; 15: 1663-1669. PMID: 17579574
25. Monia B, Johnston JF, Sasmor H, Cummine LL. Nuclease resistance and antisense activity of modified oligonucleotides targets to Ha-ras. J. Biol. Chem. 1996; 271: 14533-14540. PMID: 8662854
26. Franke C, Matschl U, Bruns M. Enzymatic treatment of duck hepatitis B virus: topology of the surface proteins for virions and non-infectious subviral particles. Virology. 2007; 359: 26-136.
27. Cheng J, Imanshi H, Morisaki H, Liu W, Makamura H, Morisaki T, Hada T. Recombinant HBsAg inhibits LPS-induced COX-2 expression and IL-18 production by interfering with the NFκB pathway in a human monocytic cell line, THP-1. J Hepatol. 2005; 43: 465-471. PMID: 15963597
28. Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HLA, van der Molen RG, Woltman AM. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology. 2008; 126: 280-289. doi: 10.1111/j.1365-2567.2008.02896.x PMID: 18624732
29. Shi B, Ren G, Hu Y, Wang S, Zhang Z, Yuan Z. HBsAg inhibits INF-α production in plasmacytoid dendritic cells through TNFα and IL-10 induction in monocytes. PLoS ONE. 2012; 7: e44900. PMID: 23024774
30. Vanlandschoot P, Van Houtte F, Roobrouck A, Farhoudi A, Lerous-Roels G. Hepatitis B virus surface antigen suppresses the activation of monocytes through interaction with a serum protein and a monocyte-specific receptor. J Gen Virol. 2002; 82: 1281-1289.
31. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa J-P, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak J. Hepatitis B virus suppresses Toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology. 2009; 49: 1132-1140. doi: 10.1002/hep.22751 PMID: 19140219
32. Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang Z, Shen F, Zhang Q, Sun S, Yuan Z HBsAg inhibits TLR-9-mediated activation and INF-α production in plasmacytoid dendritic cells. Mol Immunol. 2009; 46: 2640-2646. doi: 10.1016/j.molimm.2009.04.031 PMID: 19501403
33. Burda MR, Gunther S, Dandri M, Will H, Petersen J. Structural and functional heterogeneity of naturally occurring hepatitis B virus variants. Antiviral Res. 2001; 52: 125-138 PMID: 11672822
34. Cooreman MP, Leroux-Roels G, Paulij WP. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci. 2001; 8:237-247. PMID: 11385295
35. Hsu CW, Yeh C-T. Emergence of Hepatitis B Virus S gene Mutants in Patients Experiencing Hepatitis B Surface Antigen Seroconversion After Peginterferon Therapy. Hepatology. 2011; 54: 101-108. doi: 10.1002/hep.24363 PMID: 21503942
36. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Büschenfelde KH et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology. 1998; 27: 254-63. PMID: 9425945
37. Al-Mahtab M, Bazinet M., Vaillant A. Effects of nucleic acid polymer therapy alone or in combination with immunotherapy on the establishment of SVR in patients with chronic HBV infection. J. Clin. Virol. 2015; 69: 228.
38. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterol. 2004; 126: 1750-1758.
39. Wong DK, Seto W-K, Fung J, Ip P, Huang F-Y, Lai C-L et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol. 2013; 11: 1004-1010. doi: 10.1016/j.cgh.2013.01.026 PMID: 23376799